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Increased protein supply by feeding cow-milk-based infant formula in comparison to lower protein content of human milk is a
well-recognized major risk factor of childhood obesity. However, there is yet no conclusive biochemical concept explaining the
mechanisms of formula-induced childhood obesity. It is the intention of this article to provide the biochemical link between
leucine-mediated signalling of mammalian milk proteins and adipogenesis as well as early adipogenic programming. Leucine
has been identiﬁed as the predominant signal transducer of mammalian milk, which stimulates the nutrient-sensitive kinase
mammalian target of rapamycin complex 1 (mTORC1). Leucine thus functions as a maternal-neonatal relay for mTORC1-
dependent neonatal β-cell proliferation and insulin secretion. The mTORC1 target S6K1 plays a pivotal role in stimulation
of mesenchymal stem cells to diﬀerentiate into adipocytes and to induce insulin resistance. It is of most critical concern that
infant formulas provide higher amounts of leucine in comparison to human milk. Exaggerated leucine-mediated mTORC1-
S6K1 signalling induced by infant formulas may thus explain increased adipogenesis and generation of lifelong elevated adipocyte
numbers. Attenuation of mTORC1 signalling of infant formula by leucine restriction to physiologic lower levels of human milk
oﬀers a great chance for the prevention of childhood obesity and obesity-related metabolic diseases.
1.Introduction
Obesity is a serious health problem of Westernized societies
with a prevalence of up to 25% with an increasing incidence
in children [1]. Obesity is a complex disease that involves
interactions between environmental and genetic factors [2].
Approximately 25% of children in the USA are overweight
and approximately 11% are obese. From 1976 till 1991,
the prevalence rate of overweight children in the USA had
increasedbyapproximately40%[1].Type2diabetesmellitus
(T2D) in children and adolescents is an important and
increasing public health problem directly related to the
epidemic of childhood obesity [3]. High BMI at birth has
been identiﬁed as an important determinant for overweight
later in life [4]. In Western societies, maternal and postnatal
nutritions are excessive and may substantially aﬀect develop-
mental programming [5].
2.The LinkbetweenInfantFormula Feeding
andChildhood Obesity
In 1981, a case-control study of children between 12 to 18
years of age in Montreal presented ﬁrst evidence that breast
feeding protects against later obesity [6]. A cross sectional
surveyinsouthernGermany(Bavaria)assessedearlyfeeding,
diet, and lifestyle factors of 13345 children at the time of
school entry. The prevalence of obesity in children who had
never been breast fed was 4.5% as compared with 2.8% in
breast-fed children [7]. A clear dose-response eﬀect on the
prevalenceofobesitywasidentiﬁedforthedurationofbreast
feeding. Thus, breast feeding is a signiﬁcant protective factor
against the development of obesity and being overweight [7].
During the ﬁrst 6–8 weeks of life, there is little diﬀerence
in growth (gain in weight and length) between breast-
and formula-fed infants. However, from about 2 months2 Journal of Obesity
of age to the end of the ﬁrst year of life, formula-fed
infants gain weight and length more rapidly than breast-
fed infants [8]. At the end of the ﬁrst year of life, evidence
suggests that breast-fed infants are leaner than formula-
fed infants. Formula-fed infants at 4-5 months of age show
higher plasma levels of IGF-1, insulin, and certain amino
acids than breast-fed infants. Whereas the protein intake of
breast-fed infants decreases with age and closely matches
the requirements for protein during the early months
of life, the protein intake of formula-fed infants exceeds
requirements after the ﬁrst 1-2 months of life consistent with
the hypothesis that diﬀerences in protein intake are mainly
responsible for diﬀerences in growth between breast- and
formula-fed infants (early protein hypothesis)[ 8]. A double-
blinded, randomized controlled trial presented substantial
evidencethatinfantformulasprovidingahighproteinintake
during the ﬁrst year of life induced excessive weight gain in
early childhood [9]. High protein intake in early infancy has
thus been conﬁrmed to be an important risk factor for later
obesity [9, 10].
Exclusive breast feeding by a healthy mother should
be the standard from birth to at least 6 months. During
the breast feeding period, the protein intake is low in
the human being compared to many other animals. The
daily protein intake by breast feeding is approximately
1g/kg/day. When other foods are introduced during the
weaning period, the protein intake increases remarkably to
3-4g/kg/day in spite of the fact that the protein requirement
is decreasing [11]. A systematic review evaluating the ideal
quantity of dietary protein for formula-fed low-birth-weight
infants <2.5kg came to the conclusion that higher protein
intake (>3.0g/kg/day but <4.0g/kg/day) from formula in
comparisontolowerproteinintake(<3g/kg/day)accelerated
weight gain [12]. Furthermore, human milk in comparison
to infant formula contains leptin, which has been implicated
to play a role in perinatal programming of body weight and
the regulation of muscle thermogenesis [13].
3.PostnatalHigh-ProteinDietIncreases
ObesityRisk of RatsinAdulthood
Low-protein diets in the rat have probably most extensively
been used to try and elucidate mechanisms of metabolic
programming [14]. However, only few studies evaluated the
eﬀect of high protein diets on developmental programming.
A high-protein diet (40% casein wt/wt; 4% leucine) in
comparison to a normal diet (20% casein wt/wt, 2% leucine)
or to a high-ﬁbre diet (17.3% casein wt/wt; 1.7% leucine)
in Wistar rat pups weaned at day 21 was associated with
an increased susceptibility for obesity in adulthood [15].
Body weight, fat mass, and glycaemia in adult males and
fat mass in females were greater after a high-fat challenge in
these rats that consumed a high protein diet from weaning
[15, 16]. High-protein diet during early growth exhibited
excessive increase in fat mass in response to a high-fat and
-sucrose diet in adult rats as well as elevated leptin levels
during oral glucose challenge [17]. Maternal diet during
pregnancy and lactation as well as early-postnatal feeding
are thus critical periods during which intervention strategies
could be developed to reduce the prevalence of obesity [18].
4. Mammalian Milk: A SignallingSystem for
Neonatal Growth
Information on the potential endocrine mechanisms of milk
protein signalling is very scarce. So far, most attention
has been paid to the role of IGF-1 as the driving mech-
anism of milk-mediated growth [19–26]. IGF-1 has been
shown to stimulate the diﬀerentiation of preadipocytes to
adipocytes [27, 28]. Moreover, the branched-chain amino
acids (BCAAs) leucine, isoleucine, and valine have been
implicated to be involved in growth promoting eﬀects of
milk,becausetheyarephysiologicstimuliofinsulinsecretion
[29,30].BothinsulinandIGF-1havemitogenicandanabolic
eﬀects and stimulate lipogenesis and adipogenesis [31].
It has recently been emphasized that mammalian milk
is the most important endocrine species-speciﬁc signalling
systemthatpromotesneonatalgrowthbyincreasinginsulin-,
IGF-1-, incretin-, and leucine-mediated mammalian target
of rapamycin complex 1- (mTORC1-) signalling of pan-
creatic β-cells [32]. Milk signalling is predominantly based
on milk proteins, evolutionarily well-conserved secretory
products of the mammalian lactation genome, which are
essential for growth and survival of mammalian neonates,
and have been established more than 160 million years ago
[33]. Remarkably,among all mammalian species, the average
protein content of milk in humans is the lowest and has been
determined to be 1.21g protein/100mL of mature human
milkduringtheﬁrst3monthsoflactationand1.14g/100mL
at 6 months of lactation, respectively [34]. Recent data of
human milk (>15 days postpartum) found protein values
of 1.26g/100mL during the day period and 1.35g/100mL
during the night, respectively [35]. In contrast, cow milk
contains 3.36g protein/100mL.
5.Total LeucineUptake by MammalianMilk
andNeonatal GrowthRate
Intriguingly, the protein content of mammalian milk of
various species is related to the rate of growth of the
oﬀspring [36]. Human neonates, who receive the lowest
protein content of milk among mammalian species, require
180 days to double their birth weight in comparison to
calves who double their birth weight already after 40 days.
The highest milk protein concentrations are found in rat
or rabbit in the range of 8.7g/100mL and 10g/100mL,
respectively, who double their birth weight already after 4
to 5 days [36]. Thus, there is a correlation between the
species-speciﬁc protein concentration of mammalian milk
and the growth rate of the neonate (Table 1). Remarkably,
the amount of leucine per gram milk protein appears to be
a mammalian species-independent constant in the range of
100mg leucine/g milk protein for humans, various primates,
and nonprimate species including cow [37]( Table 2). Thus,
the total amount of milk protein fed to a mammalian
neonate correlates to the total leucine uptake provided byJournal of Obesity 3
Table 1: Leucine content of mammalian milk and growth rate.
Species
Protein
content of milk
(g/100mL)
Leucine
content of milk
(mg/100mL)
Days (n) for
doubling
birth weight3
Rat1 8.7 799 4
Cow1 3.4 333 40
Infant formula
(HP)2 3.2 308 ?
Infant formula
(LP)2 1.6 154 ?
Human milk2 1.2 104 180
1Data according to Davis et al. [37]; 2HP = high protein followon infant
formula; LP = low protein followon infant formula at 6 months of age [39].
3Data according to Bounous et al. [36].
Table 2: Leucine content per g total milk protein in various
species∗.
Species Total amino acids g/100mL
whole milk
Leucine content mg/g
total amino acids
Human 0.85 104
Chimpanzee 0.92 104
Gorilla 1.15 102
Baboon 1.15 105
Rhesus 1.16 111
Horse 1.58 93
Goat 2.57 96
Llama 2.96 99
Cow 3.36 99
Pig 3.50 89
Elephant 3.71 98
Sheep 5.41 90
Cat 7.57 118
Rat 8.69 92
Range: 0.85–8.69g/100mL Mean: 100 ± 8mg/g
protein
∗Data derived from Davis et al. [37].
milk of the mammalian species and appears to be associated
with leucine-mediated growth. These observations are in
accordance with premature infants fed formula containing a
higher protein concentration who gained weight faster than
those fed formulas with a lower protein concentration closer
to that of human milk [38].
6. Milk Proteins:The Richest AnimalProtein
Source of Leucine
Among all animal proteins, milk proteins contain the highest
amount of leucine. Highest leucine levels are found in the
water-soluble and easily digestible whey protein fraction
in the range of 14% [40]. An important leucine carrier
is the whey protein α-lactalbumin. Bovine and human α-
lactalbumin contain 10.4% and 11.3% leucine, respectively
[41]. Whey proteins and especially α-lactalbumin exert a
high insulinaemic response, which is predominantly medi-
ated by the insulinotropic activity of leucine [42].
The bulk of cow milk proteins are contained in the
casein fraction (80%). Bovine caseins contain on average
10% leucine. Egg protein (8.5% leucine) and meat protein
(8% leucine) contain less leucine than milk proteins, the life
starterproteinsofmammalianevolution[40].Tounderstand
the role of milk-mediated leucine signalling, the most
critical regulatory function of the leucine-dependent kinase
mammalian target of rapamycin complex 1 (mTORC1) has
to be discussed in more detail.
7. mTORC1: The Central Growth Regulator of
Mammalian Cells
Leucine as well as the growth hormones insulin and
IGF-1 are important activating stimuli of the nutrient-
sensitive kinase mTORC1, a central cell growth regulator
conserved from yeast to mammals [43–49]. Amino acids
and predominantly leucine are the most critical signals for
mTORC1signallingandarerequiredformTORC1activation
by growth factors like insulin and IGF-1 [49]( Figure 1).
Recent discoveries in the ﬁeld of molecular biology have
established the key role of mTORC1 in the regulation of
multiple central cell functions including gene transcrip-
tion, translation, ribosome biogenesis, protein synthesis,
cell growth, cell proliferation, lipid synthesis, mitochon-
drial activity, and suppression of autophagy [44–47]. The
ribosomal S6 kinase (S6K1) and the eukaryote translation
initiationfactor4Ebindingprotein(4E-BP1)arethetwobest
characterizedmTORC1substrates.Theirphosphorylationby
mTORC1 mediates the function of mTORC1 in regulating
translation[43,44].mTORC1hasbeenidentiﬁedasthemost
important convergence point of nutrient-derived signalling
and is thus of pivotal importance for neonatal growth [50].
mTOR is a multidomain protein of approximately
300kDa exhibiting a protein kinase domain at its C-
terminus related to phosphoinositol-3-kinases (PI3Ks). In
mammalian cells, two functionally diﬀerent mTOR com-
plexes exist: mTORC1 and mTORC2, respectively. Among
other functional proteins, mTORC1 contains the important
partner protein raptor, which interacts with substrates for
mTORC1-mediated phosphorylation. mTORC1 controls the
G1/S transition and G2/M progression of the cell cycle
[51]. In contrast to mTORC2, which contains the partner
protein rictor, only mTORC1 plays a special role in sensing
cellular nutrients, amino acids, and energy (ATP) levels
important for cell growth and proliferation. LKB1 and AMP-
activated protein kinase (AMPK) are critical regulators of
mTORC1 [52]. Most functions of mTORC1 are inhibited
by rapamycin, a triene macrolide antibiotic synthesized by
Streptomyces hygroscopicus [44, 47]. Growth factor signals
like insulin and IGF-1 are integrated by the tuberous scle-
rosus proteins TSC1 (hamartin) and TSC2 (tuberin), which
form a complex that regulates Rheb (ras homolog enriched
in brain), the ﬁnal activator of mTORC1 [53–57]( Figure 1).
Growth factor signalling via TSC2 phosphorylation reduces4 Journal of Obesity
LAT IR IGF1R GLUT
IRS-1
PI3K Akt
AMPK
Rag GTPases
Translocation
Inactive
mTORC1
ATP
Leucine
Leucine
Insulin IGF-1 Glucose
Rheb
4E-BP1 S6K1 SREBP1
TSC1/TSC2
mTORC1 activated
Figure 1: Simpliﬁed model of leucine-, insulin/IGF-1-, and
glucose-dependent activation of mTORC1; Akt: Akt kinase; AMPK:
AMP-activated protein kinase; ATP: adenosine triphosphate; 4E-
BP1: eukaryotic initiation factor (eIF) 4E-binding protein 1; GLUT:
glucose transporter protein; IGF-1: insulin-like growth factor
1; IGF1R: IGF-1 receptor; IR: insulin receptor; IRS-1: insulin
receptorsubstrate1;LAT:L-typeaminoacidtransporter;mTORC1:
mammaliantargetofrapamycincomplex1;PI3K:phosphoinositol-
3 kinase; Rheb: ras homolog enriched in brain; S6K1: p70 S6 kinase
1; SREBP: sterol regulatory element-binding transcription factor;
TSC1: tuberous sclerosis complex 1 (hamartin); TSC2: tuberous
sclerosis complex 2 (tuberin).
the inhibitory function of TSC1/TSC2 towards Rheb, which
resultsinactivationofRhebandﬁnallyofmTORC1[53–57].
mTORC1 has to be regarded as a key node in cell signalling,
because it integrates many intra- and extracellular signals
such as growth factors (insulin, IGF-1), energy-sensing
signals (glucose, AMP/ATP ratio regulating AMPK), and
most importantly the availability of amino acids, especially
leucine for mTORC1 activation [45, 49, 50]( Figure 1).
8.Amino-Acid-MediatedActivationofmTORC1
Two parallel mechanisms of mTORC1 activation have been
identiﬁed: (1) the upstream activation of the small GTPase
Rheb by growth factor signals and high glucose/ATP levels,
and (2) the amino-acid-mediated Rag GTPase-dependent
translocation of inactive mTORC1 to active Rheb local-
ized at late endosome or lysosome compartments [58–61]
(Figure 1). Moreover, mTORC1 activity is regulated by Rab
and Arf family small GTPases, which stimulate mTORC1
activation by the regulation of intracellular traﬃcking in
response to amino acids [62]. Raptor has been identiﬁed as
an interacting partner of the signalling adaptor p62, which
is an integral part of mTORC1 and is necessary to mediate
amino-acid signalling for the activation of S6K1 and 4E-
BP1 [63]. p62 interacts in an amino acid-dependent manner
with mTORC1 and raptor and binds the Rag proteins and
favours formation of the active Rag heterodimer that is
further stabilized by raptor. Interestingly, p62 colocalizes
with Rags at the lysosomal compartment and is required for
theinteractionofmTORC1withRagGTPasesinvivoandfor
translocation of mTORC1 to the lysosome, a crucial step for
mTORC1 activation [63, 64]( Figure 1). Recent evidence has
been provided that mTORC1 also senses lysosomal amino
acids through an inside-out mechanism that requires the
vacuolar H+-ATPase [65].
9. Primacy of Leucine for mTORC1 Activation
Essential BCAAs are important for the regulation of growth,
protein biosynthesis, and metabolism [45, 49]. There is
substantial evidence that from all amino acids, leucine
plays a major role in mTORC1 activation [43, 64]. The
system L amino acid transporter 1/2 and the 4F2hc/CD98
glycoprotein are the primary route for cellular entry of
neutral amino acids, such as leucine. The accumulation of
intracellular amino acids is believed to be achieved by system
A transporter, such as SNAT2 (sodium-coupled neutral
amino acid transporter 2) [66]. Expression of both system
L (LAT1/CD98) and system A (SNAT2) positively correlated
with mTORC1 activity [67, 68]. Their functional coupling
may explain why glutamine is required for the stimulating
eﬀectofleucineonmTORC1activity[69,70].Thereciprocal
exchange of intracellular glutamine for extracellular leucine
is important for activation of mTORC1 and its downstream
target S6K1 [71–73]. Since mTORC1 signalling positively
stimulates protein synthesis, it makes physiological sense
that mTORC1 signalling is tightly regulated by amino acid
availability. Withdrawal of leucine in cell culture was nearly
as eﬀective in downregulation of mTORC1 signalling as
withdrawal of all amino acids [43]. The preeminent eﬀect
of leucine withdrawal has been consistently observed in
a variety of cell types, thus underlining the primacy of
leucine in amino-acid-mediated mTORC1 regulation [45].
Ratplasma levels of leucine werelinearly related to the intake
of gram protein diet regardless of the dietary source [74].
In humans, the highest postprandial leucine concentrations
have been measured after a whey protein meal, followed by a
milk meal and a cheese meal, respectively [42]. The strongest
correlation between postprandial insulin responses and early
increments in plasma amino acids was demonstrated for
leucine,valine,lysine,andisoleucine.Incomparisontoother
amino acids, leucine exhibited the highest insulinogenic
index [42]. Thus, leucine plays a crucial role for mTORC1
activation, β-cell growth, β-cell proliferation, and insulin
secretion [42, 43, 45, 49].
10. Leucine-mTORC1-Dependent β-Cell
Proliferation and InsulinSecretion
Insulin is an anabolic and mitogenic hormone important for
neonatal growth. Both insulin and IGF-1 are involved in the
regulation of adipogenesis [28, 31]. Thus, the regulation of
insulin secretion by mammalian milk plays a critical role for
infant and adipose tissue growth. Despite a low carbohydrate
moiety and a low glycaemic index, both whole cow milk
as well as skim milk exhibit a high insulinaemic indexJournal of Obesity 5
(>100), which depends on milk’s insulinotropic protein
fraction [75, 76]. It is the biological function of milk to
promote neonatal growth by stimulating neonatal β-cell
mass expansion and insulin secretion. Like in all other
peripheral cells, the mTORC1 pathway is highly active in
β-cells and plays a central role in leucine-mediated β-cell
proliferation and insulin secretion [77]. Leucine activates
mTORC1 independent of insulin [29, 30]. The pancreatic β-
cells express a variety of growth factor receptors, which stim-
ulate mTORC1 and promote β-cell growth and replication
[78]. Insulin and IGFs in concert with leucine, glutamine,
and glucose modulate protein translation through mTORC1
in β-cells [29, 30]. Glucose robustly activates mTORC1 in an
amino-acid-dependent manner in rodent and human islets
[29]. In contrast, the mTORC1 inhibitor rapamycin dose-
dependently inhibited DNA synthesis of rat islets exposed
to elevated levels of glucose [29]. mTORC1/S6K1/4E-BP1-
signalling is known to control cell size and proliferation
by increasing mRNA translation and cell cycle progression
[44, 51, 78]. Leucine has already been demonstrated to
activate the translational regulators, phosphorylated heat-
and acid-stable protein regulated by insulin (PHAS-I) and
S6K1, in an mTORC1-dependnet manner [79]. Leucine-
induced insulin secretion of β-cells involves increased mito-
chondrial metabolism by oxidative decarboxylation and
allosteric activation of glutamate dehydrogenase. Leucine
is essential for activation of protein translation through
mTORC1 and contributes to enhanced β-cell function
by stimulating growth-related protein synthesis and β-cell
proliferation [79, 80]. mTORC1 activation in β-cells of
TSC2-deﬁcient mice (βTSC2−/−) increased mitochondrial
biogenesis and enhanced insulin secretion [81]. In contrast,
S6K1-deﬁcient mice displayed hypoinsulinaemia, glucose
intolerance, and diminished β-cell size [82]. Thus, there
is substantial evidence for the crucial role of leucine in
mTORC1-S6K1-mediated activation increasing β-cell pro-
liferation, protein translation, and insulin synthesis [77–
82]. The most important function of leucine-transmitted
milk signalling is the stimulation of insulin secretion, a
fundamental growth-promoting mechanism for insulin-
mediated mTORC1 signalling of insulin-sensitive peripheral
cells of the body including adipocytes.
11.ExcessiveLeucineUptake by
InfantFormulaFeeding
Cow milk-based infant formulas currently contain almost
50% higher total protein content (2.1 to 2.2g/100kcal)
than human milk (1.8g/100kcal) [83]. Remarkably, the
protein intake per kg body weight is 55–80% higher in
formula-fed than in breast-fed infants [84]. The most recent
randomized clinical trial showed that cow-milk-based infant
andfollowonformulaspreparedwithlowerprotein(1.77and
2.2g protein/100kcal) and higher protein (2.9 and 4.4g pro-
tein/100kcal) had higher leucine content in comparison to
human milk [39]. Infant and followon formulas with lower
protein content provided 119 and 154mg leucine/100mL,
whereas infant and followon formula with higher protein
content contained 197 and 308mg leucine/100mL, respec-
tively. In comparison, human milk only contains 104mg
leucine/100mL[37,39](Table 3).Thus,theleucineamounts
provided by these infant formulas were 14.4%, 48.1%,
89.4%, and 196.2% higher compared to physiologic leucine
levels provided by human milk. At 6 months of age, serum
leucine levels of infants fed higher protein formula were
165μmol/L, and those of infants fed lower protein formula
were 120μmol/L, respectively, whereas the lowest leucine
serumlevelsweredetectedinbreast-fedinfants(106μmol/L)
(Table 3)[ 39]. Higher leucine serum levels of infants fed
higher amounts of leucine by infant formula just reﬂect the
known linear correlation between dietary amino acid intake
and amino acid serum levels [74]( Figure 2). The excessive
supply of leucine provided by infant formula is thus of most
critical concern because the availability of leucine is a crucial
determinant for the magnitude of mTORC1 activity [43, 45].
12. InfantFormulaIncreasesInsulin/IGF-1
Signals for mTORC1 Activation
Infant formula not only increases leucine signals for
mTORC1 activation but also insulin and IGF-1 signals,
which are all integrated by mTORC1 (Figure 1). It has
recently been shown that lower protein content of infant
formula was associated with lower total IGF-1 serum lev-
els (34.7ng/mL) in comparison to high protein formula
(48.4ng/mL) [39]. Remarkably, the lowest total serum IGF-
1 levels (14.1ng/mL) were detected in serum of breast-
fed infants [39]. C-peptide serum levels, a measure of
insulin secretion, were highest in infants fed the high-
protein formula (26.9ng/mL), lower in infants fed the lower-
proteinformula(19.5ng/mL),andagainthelowestinbreast-
fed infants (9.3ng/mL) [39]. Thus, the controlled feeding
study of Socha et al. [39] provided strong evidence that
infant formula in comparison to human milk signiﬁcantly
increases serum levels of leucine, insulin, and IGF-1, all
most important stimulatory signals for mTORC1 activation
[49, 50].
13.mTORC1 SignallingandMilk-Induced
InsulinResistance
The major substrate of mTORC1 is the kinase S6K1 [43].
S6K1 phosphorylates Ser-307 of insulin receptor substrate-1
(IRS-1) and thereby activates an important feedback mech-
anism, which downregulates insulin signalling by inducing
insulin resistance [85–87]. High mTORC1 signalling is thus
associated with a higher degree of S6K1-mediated insulin
resistance. Remarkably, absence of S6K1 protected S6K1−/−
mice against age- and high-fat-diet-induced obesity while
enhancing insulin sensitivity, pointing to the crucial role
of the mTORC1-S6K1 pathway in the regulation of insulin
signalling and the induction of nutrient-induced insulin
resistance due to hyperactivated S6K1 [88]. In humans,
insulin resistance has been induced by infusions of high con-
centrations of amino acids, whereas the mTORC1 inhibitor
rapamycin improved insulin action [89]. Infusion of an6 Journal of Obesity
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Figure 2: Linear correlation between oral leucine intake by the
infant feeding and the infant’s serum leucine concentrations.
aminoacidmixturetohealthymenresultedinplasmaamino
acid elevations, hyperinsulinaemia, and marked activation
of S6K1 with increased inhibitory IRS-1 phosphorylation
[90]. Infusion of amino acids containing 8.9g/L leucine
impaired insulin-mediated suppression of glucose produc-
tion and insulin-stimulated glucose disposal in skeletal
muscle. Insulin resistance was also observed after incubation
of rat skeletal muscle with higher concentrations of both
leucine and glucose [91]. In accordance with these ﬁndings,
are the results of feeding studies of rats with a high-fat diet
supplemented with BCAAs exhibiting chronic mTORC1-
mediated phosphorylation of IRS-1 at Ser-307, which was
reversed by rapamycin treatment [92]. Moreover, the dietary
pattern that includes high fat consumption accompanied
with high amounts of BCAAs appears to contribute to
obesity-associated insulin resistance [92]. Thus, there is
substantial evidence that the amount of leucine and other
BCAAs, regulate mTORC1-S6K1 signalling, an important
pathway leading to insulin resistance.
Remarkably, the daily intake of 53g cow-milk protein
containing 5.7g leucine in 8-year-old boys resulted in
increased insulin secretion and the induction of insulin
resistance [22]. Milk-protein-induced insulin resistance can
be well explained by leucine-mTORC1-mediated activation
of S6K1. Higher leucine/isoleucine serum levels (median
170.0μM)ofobesesubjectshavebeenshowntobeassociated
with a higher HOMA of 5.73 in comparison to lower
leucine/isoleucine serum levels (149.0μM) of lean subjects
exhibiting a lower HOMA of 2.51 [92].
The magnitude of leucine-mTORC1 signalling for nor-
m a lg r o w t hd i ﬀers in various mammalian species. The
highest leucine intake per volume milk is found in small-
fast growing rodents. Calves duplicate their birth weight
already after 40 days, whereas human infants are the
mammals with the slowest growth rate, duplicating their
Table 3: Leucine content of infant diet and serum leucine levels.
Type of infant
diet
Protein
content of
infant diet
(g/100mL)
Leucine
content of
infant diet
(mg/100mL)
Serum
leucine levels
(μmol/L)
Human milk1
whey/casein 3:2 1.21 104 106
Low-protein (LP)
infant formula2 1.25 119 1104
LP followon
formula2 1.60 154 120
High-protein
(HP) infant
formula2
2.05 197 1334
HP followon
formula2 3.20 308 165
Cow milk
whey/casein 1:5 3.40 3333 1724
1DataderivedfromNommsenetal.[34]; 2dataaccordingtoSochaetal.[39]
with low- and-high protein infant formulas with a whey/casein ration 1:4;
3leucine data according to Davis et al. [37]; 4leucine serum levels calculated
according to Johnson et al. [74].
birth weight after 180 days (Table 1). Thus, each species
appears to have its own milk-mediated leucine-mTORC1
signalling axis (Table 2). Remarkably, cow-milk-mediated
leucine-mTORC1 signalling greatly exceeds the much lower
leucine-mTORC1 signalling maintained by human milk
(Figure 2).
Early postnatal restriction or overfeeding of mice with
mouse milk resulted in metabolic abnormalities in adult life
[93]. Underfed mice exhibited impaired insulin secretion,
whereas overfed mice, which received more milk protein
and thus more total leucine during the early postnatal
period, developed insulin resistance in adult life [93].
The study of Socha et al. [39] implies the presence of
higher insulin resistance in infants fed high-protein formula
(ratio C-peptide 26.9ng/mL: fasting glucose 83mg/dL) in
comparison to low-protein formula (C-peptide 19.5ng/mL:
glucose 85mg/dL). The lowest level for insulin resistance
was detected in breast-fed infants (C-peptide 9.3ng/mL:
glucose 86mg/dL) [39]. Thus, human milk in comparison to
infantformulainducedthelowestdegreeofinsulinresistance
reﬂecting the lowest magnitude of mTORC1-S6K1-IRS-1
signalling during physiological breast feeding in comparison
to artiﬁcial formula feeding.
14. Adipogenic Effects of Leucine
Adipose tissue like muscle is a major extrahepatic site
of leucine metabolism. Notably, leucine is an important
precursor of fatty acid and cholesterol biosynthesis [94].
Most importantly, in adipocytes, leucine has been shown
to be the main regulatory amino acid activating mTORC1,
S6K1, and 4E-BP1 [95, 96]. mTORC1 plays a crucial role
in adipocyte regulation including hypertrophic growth,
leptin secretion, protein synthesis, and adipose tissue mor-
phogenesis [96, 97]. The mTORC1 antagonist rapamycinJournal of Obesity 7
has been shown to block adipocyte diﬀerentiation [98].
Rapamycin speciﬁcally disrupted the positive transcriptional
feedback loop between CCAAT/enhancer-binding protein-α
a n dp e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r - γ (PPARγ),
two key transcriptional factors in adipogenesis, by directly
targeting the transactivation of PPARγ [99]. Remarkably,
PPARγ activity was dependent on amino acid suﬃciency,
linking amino acid status to adipogenesis [99]. In isolated
adipocytes, amino acids, and primarily leucine, stimulated
phosphorylation of 4E-BP1 and S6K and induced multicel-
lular clustering in adipocytes [100, 101]. mTORC1 signalling
aloneissuﬃcienttoregulateadipogenesis,becauseactivation
of mTORC1 causes a robust increase in mRNA and PPARγ
protein expression despite severe insulin resistance and
the absence of Akt signalling [102]. Furthermore, it has
been demonstrated that the adipogenic eﬀect of insulin
is mediated by insulin’s stimulatory eﬀect on the Akt-
TSC2-mTORC1 pathway [102]. Thus, it is conceivable that
leucine-enriched infant formulas in comparison to human
milk exert higher leucine-, insulin-, and IGF-1-mediated
stimulatory eﬀects on mTORC1 of mesenchymal stem cells
and adipocytes. In fact, it has recently been shown in
S6K1−/− mice that lack the mTORC1 downstream target
S6K1 impaired the generation of de novo adipocytes when
these mice were challenged with a high-fat diet, consistent
with a reduction in early adipocyte progenitors [103]. Thus,
leucine-mediated activation of mTORC1-S6K1 signalling
plays a fundamental functional and substrate role in adi-
pogenesis and serves as a pivotal amino acid stimulator of
the mTORC1-S6K1 pathway, which drives S6K1-dependent
commitment of embryonic stem cells to early adipocyte
progenitors,stimulatesadipocytediﬀerentiationviacrosstalk
with PPARγ upregulation and serves as a lipid substrate for
adipocyte de novo lipid synthesis [96–103]. The importance
ofmTORC1-S6K1signallinginadipogenesisbecomesappar-
ent in S6K1-deﬁcient mice, which are protected against age-
and diet-induced obesity while enhancing insulin sensitivity
[88].
ThereisanotherimportantﬁndingimplicatingmTORC1
signalling in adipogenesis. mTORC1 promotes the function
of sterol (SREBP regulatory element binding transcription
factor), a master regulator of lipo- and sterologenic gene
transcription. mTORC1 regulates SREBP by controlling the
nuclear entry of lipin 1, a phosphatidic acid phosphatase.
Dephosphorylated, nuclear, catalytically active lipin-1 pro-
motes nuclear remodelling and mediates the eﬀects of
mTORC1 on SREBP target genes, SREBP promoter activ-
ity, and nuclear SREBP protein abundance [104]. Hepatic
triglycerides and SREBP-1 mRNA concentrations increased
signiﬁcantly in rats fed a 30% casein diet for one month
[105]. Thus, mTORC1 is not only a central regulator
of protein biosynthesis but also of lipid biosynthesis by
regulation of SREBP-1, the key transcription factor of lipid
synthesizing enzymes [106].
The recent insights into leucine-mediated mTORC1
signalling allow the conclusion that higher leucine uptake
provided by higher milk protein consumption may increase
g e n e ra lgr o wt ha sw e lla sB M I .I nf a ct ,h i gh e rm i l kc o n s u m p -
tion in children has been associated with increased linear
growth and BMI [107, 108]. Milk-stimulated acceleration
of growth may be well explained by leucine-, insulin-, and
IGF-1-mediated mTORC1 activation resulting in increased
diﬀerentiation of mesenchymal stem cells into adipocytes,
osteoblasts, and myocytes, thus promoting adipogenesis,
bone growth, as well as myogenesis [109]. In fact, high
consumption of whole cow’s milk in infancy has unfortunate
eﬀects on growth, especially weight acceleration and devel-
opment of overweight in childhood [19, 110].
15. mTORC1andPlacentalAminoAcidTransfer
for Fetal Growth
m T O R C 1p l a y sak e yr o l ef o rt r o p h o b l a s tg r o w t ha n d
diﬀerentiation and L-system-mediated amino-acid uptake
of trophoblast cells, which is most important for fetal
growth [111–113]. The activity of placental amino acid
transporters is decreased in intrauterine growth restriction
(IUGR). As mTORC1 regulates the activity of the placental
L-type amino acid transporter system, the decrease of
placentalmTORC1activityinIUGRjustexplainsdiminished
supply of leucine for mTORC1-dependent fetal growth
[114, 115]. Maternal protein restriction in rats inhibited
mTORC1signallinganddownregulatedplacentalaminoacid
transporters [116]. Leucine-rich maternal diet appears to be
an important determinant for leucine-stimulated placental-
mTORC1-dependent amino acid transfer to the fetus and
thus for leucine-mTORC1-dependent fetal growth. Thus,
impaired intrauterine growth by protein restriction during
pregnancy may be well explained by insuﬃcient leucine-
mediated mTORC1 signalling of fetal tissues.
16.mTORC1 andEarlyDevelopmental
Programming
The periods of fetal growth and postnatal growth are a
continuum and are both intimately connected to prenatal
and postnatal mTORC1 signalling and nutrient and espe-
cially leucine availability. After birth, maternal leucine is no
longer provided by the placental leucine transport system
but by the secretory leucine-rich family of mammalian milk
proteins. The essential role of mTORC1 signalling for early
development is illustrated by the early postimplantation
lethality after disruption of the mouse mTOR gene [117].
Moreover, mTOR−/− embryos displayed a lesion in inner cell
mass proliferation, consistent with the inability to establish
embryonic stem cells from mTOR−/− embryos [117]. Inacti-
vation of mTORC1 kinase activity resulted in reduced cell
size, diminished cell proliferation, and cell cycle arrest of
embryonic stem cells [118]. Transcriptome analysis of fetal
baboon kidneys in response to maternal nutrient restriction
provided further evidence that mTORC1 is involved in
developmental programming of the fetal kidney [119].
Accumulating evidence underlines the important role of
mTORC1-S6K1 signalling in mesenchymal stem cell devel-
opmentandmTORC1-dependentregulationofadipogenesis
[99–102, 109]. Remarkably, deﬁcient mesenchymal stem cell
diﬀerentiation into adipocytes has been observed in S6K1−/−8 Journal of Obesity
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Figure 3: Linear correlation between milk-derived leucine intake
of pregnant mothers and increase of the infants’ birth weight. Data
o b t a i n e df r o mO l s e ne ta l .[ 120].
mice [103]. Conversely, it can be concluded that increased
leucine supply during pregnancy by leucine-rich diets like
increased dairy protein consumption during pregnancy may
be associated with increased fetal growth and higher birth
weight. Indeed, increased dairy protein consumption during
pregnancy has been clearly correlated with increased size and
birth weight of human neonates [120]( Figure 3).
Continued high leucine supply to the neonate by
leucine-richinfantformulamayoverstimulatethemTORC1-
dependent process of mesenchymal stem cell diﬀerentiation
into adipocytes. Thus, human overnutrition with leucine-
rich protein sources provided by Western diet during
pregnancy as well as postnatal infant feeding with leucine-
rich infant formula may be fundamental factors promoting
higher numbers of adipocytes, a long-term adverse eﬀect of
early adipogenic programming.
17.HypothalamicmTORC1 Signalling
ControlsFoodIntake
There is recent concern that formula-mediated regulation
of central satiety signalling deviates from natural satiety
regulation of breast feeding. The anorexigenic hormone
leptin is primarily synthesized by adipose tissue and reduces
food intake by central action on the arcuate nucleus and
the ventromedial hypothalamus [121]. It has been shown
that addition of leucine to isolated rat adipocytes stimulated
leptinexpressionviaanmTORC1-dependentpathway[122].
Furthermore, long-term leucine supplementation in old rats
promoted hypertrophy and hyperplasia of adipose tissue
associated with increased mTORC1/S6K1 activation [123].
Serum leptin levels correlate with adipose tissue levels in
both animals and humans and show a stronger correlation
with fat mass than total body mass [124]. A dietary
pattern that includes high fat consumption accompanied
with high amounts of BCAAs appears to contribute to
obesity-associated insulin resistance and increased serum
leptin levels [92]. Thus, leucine appears to act as a signal
nutrient that relays adipocte leptin release, which ﬁnally
exerts leptin-mediated central regulations of food intake.
Intriguingly, recent observations have suggested a poten-
tial role for mTORC1 as a cellular fuel sensor in the
hypothalamic circuits that regulate energy balance [125,
126]. mTORC1 is critically involved in mediating leptin-
induced anorexia [127]. Under physiological conditions,
increased hypothalamic availability of leucine stimulates
mTORC1 activity and reduces food intake in an mTORC1-
dependent manner. Hypothalamic mTORC1 activity is also
required for the suppression of feeding by leptin [127].
However, long-term activation of the mTORC1 pathway
by deletion of TSC1 with Pomc/Cre (Pomc-Tsc1cKO mice)
impairsthefunctionofanorecticPomcneuronsandinduced
hyperphagic obesity [126]. Recent evidence points to a
complexcell-type-dependentmTORC1-mediatedregulation
in the basomedial hypothalamus by leptin and nutritional
status [128]. Remarkably, rats maintained on a high-fat
diet had no anorexic response to intracerebroventricular
leptin [129]. Under high-fat diet, leptin was unable to
modulate hypothalamic mTORC1 signalling [129]. CNS
leptin resistance by obesigenic diets is therefore, thought
to override CNS regulatory circuits otherwise assuring
the maintenance of energy balance. Long-term abnormally
high leucine intake provided by infant formula may thus
induce a state of chronically imbalanced leptin-mTORC1
signalling promoting “orexigenic metabolic programming”
of mTORC1-dependent hypothalamic regulatory networks.
18. Conclusions
There is substantial evidence that breast feeding in com-
parison to cow-milk-based formulas supplies much lower
amounts of leucine to the infant and thus transduces
lower leucine-mediated stimulatory eﬀects on mTORC1
signalling of the neonate (Figure 4). Infant formula feeding
in comparison to breast feeding results in excessive serum
levels of leucine, insulin, and IGF-1, explaining exagger-
ated mTORC1-dependent early adipogenic programming,
the promoting mechanism for early onset of childhood
obesity. In comparison to lower levels of mTORC1 signalling
mediated by human milk, available cow-milk-based infant
formulas transduce increased mTORC1 signalling. Although
recent eﬀorts are made to decrease the formulas’ total
protein content [130, 131], leucine levels even of these low-
protein formulas still exceed leucine amounts of human
milk [39]. The preparation of whey-predominant infant
formula and the addition of increased amounts of bovine
α-lactalbumin allow a reduction of total protein content
[130, 132–134], however, these procedures do not normalize
the elevated leucine content, as whey proteins are carriers of
high amounts of leucine. In fact, breast feeding is associated
with less weight gain per months (595g) in comparison toJournal of Obesity 9
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Figure 4: Comparison between physiologic human milk-mediated mTORC1 signalling and exaggerated adipogenic mTORC1 signalling by
feeding leucine-rich infant formula (abbreviations see Figure 1).
standardformula(730g)orα-lactalbumin-enrichedformula
(707g), respectively [132].
There are further most serious concerns of the adi-
pogenic impact of formula feeding as mothers often use
higher than recommended amounts of formula powder for
preparing infant meals. Furthermore, it is not uncommon
that parents switch too early from low protein preformula
to higher protein followon formulas to keep their infants
asleep during the night. Moreover, the total daily volume
of formula given to the infant is not naturally restricted in
comparison to daily limitations of milk volume by breast
feeding. As the postnatal phase is the most critical period
for metabolic programming, it is a serious matter of public
health to increase the compliance for breast feeding and to
provide much more supervision and education for parents
feeding formula.
Exaggerated formula-induced mTORC1 signalling
appears to be the most critical factor for the early
development of childhood obesity and other mTORC1-
driven chronic diseases of civilization especially T2D and
cancer [135–139]. Future postnatal feeding studies in
animals, preferably primates, should clarify the eﬀect of
increased versus physiologic leucine intake on adipose tissue
development as well as central regulations of leucine- and
leptin-mediated food intake. Moreover, future attention
should be paid to the regulatory mechanism directing
dietary leucine either to adipogenesis or myogenesis, which
may be an important aspect in early metabolic programming
with special regard to the recently recognized molecular
cross-talk between adipose tissue and skeletal muscle [140].
Closely regulated dietary leucine ﬂuxes into various tissues
may be the most critical determinant during the neonatal
growth period when skeletal muscle activity and myogenesis
are less mind controlled. The proper adjustment of the
mTORC1-driven signalling axis by leucine restriction of
infant formula to physiologic leucine levels of human milk
oﬀers a new and most promising chance for the prevention
of early adipogenic programming and the epidemic of
childhood obesity.
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